Publications

4631 Results

Phase II studies of hydroxyurea (NSC-32065) in adults: Urologic and gynecologic neoplasms.

Authors
CD Howe;ML Samuels
Journal / Conference
Cancer Chemotherapy Reports 40:47-48
Year
1964
Research Committee(s)
Genitourinary and Gynecologic

Antileukemic activity of hydroxyurea (NSC-32065) and other urea derivatives

Authors
A Goldin;JM Venditti;JAR Mead;JP Glynn
Journal / Conference
Cancer Chemotherapy Reports 40:57-74
Year
1964
Research Committee(s)
Leukemia

Phase II studies of hydroxyurea (NSC-32065) in adults: Leukemia

Authors
CC Shullenberger
Journal / Conference
Cancer Chemotherapy Reports 40:49-50
Year
1964
Research Committee(s)
Leukemia

Phase II studies of hydroxyurea (NSC-32065) in adults: Carcinoma of the lung.

Authors
JN Bickers
Journal / Conference
Cancer Chemotherapy Reports 40:45-46
Year
1964
Research Committee(s)
Lung

Phase II studies of hydroxyurea (NSC-32065) in adults: Multiple myeloma and lymphoma.

Authors
P Davis
Journal / Conference
Cancer Chemotherapy Reports 40:51-52
Year
1964
Research Committee(s)
Lymphoma and Myeloma

Erythrokinetic abnormalities with administration of hydroxyurea (NSC-32065).

Authors
CP Alfrey Jr;RJ Karjalan;SC Dale;EP Frenkel;M Lane
Journal / Conference
Cancer Chemotherapy Reports 40:27-30
Year
1964

Megaloblastic erythropoiesis induced by hydroxyurea.

Authors
DE Bergsagel;EP Frenkel;CP Alfrey Jr;WG Thurman
Journal / Conference
Cancer Chemotherapy Reports 40:15-17
Year
1964

Pediatric clinical trials with hydroxyurea (NSC-30265).

Authors
DJ Fernbach
Journal / Conference
Cancer Chemotherapy Reports 40:37-38
Year
1964

Studies on a metabolic defect induced by hydroxyurea (NSC-30265).

Authors
EP Frenkel;WN Skinner;JD Smiley
Journal / Conference
Cancer Chemotherapy Reports 40:19-22
Year
1964

Hydroxyurea (NSC-32065): Results of a Phase I study.

Authors
KM Griffith
Journal / Conference
Cancer Chemotherapy Reports 40:33-36
Year
1964